欢迎来到《四川大学学报(医学版)》
李吉杰, 侯利莎, 朱萍等. 肿瘤新药Ⅱ期临床试验常用二阶段设计的样本含量估计及其SAS实现[J]. 四川大学学报(医学版), 2017, 48(4): 600-604.
引用本文: 李吉杰, 侯利莎, 朱萍等. 肿瘤新药Ⅱ期临床试验常用二阶段设计的样本含量估计及其SAS实现[J]. 四川大学学报(医学版), 2017, 48(4): 600-604.
LI Jijie, HOU Lisha, ZHU Ping. et al. Sample Size Calculation using SAS for PhaseⅡin Two-stage Clinical Trials of Anti-tumor Drugs[J]. Journal of Sichuan University (Medical Sciences), 2017, 48(4): 600-604.
Citation: LI Jijie, HOU Lisha, ZHU Ping. et al. Sample Size Calculation using SAS for PhaseⅡin Two-stage Clinical Trials of Anti-tumor Drugs[J]. Journal of Sichuan University (Medical Sciences), 2017, 48(4): 600-604.

肿瘤新药Ⅱ期临床试验常用二阶段设计的样本含量估计及其SAS实现

Sample Size Calculation using SAS for PhaseⅡin Two-stage Clinical Trials of Anti-tumor Drugs

  • 摘要: 目的介绍肿瘤新药Ⅱ期临床试验常用Gehan 二阶段设计及Simon 二阶段设计的设计原理和样本含量估计问题,提供 SAS宏程序快速实现其样本含量估计。方法结合二项分布的确切概率原理说明单阶段设计、Gehan 二阶段设计及两种Simon二阶段设计样本含量计算过程。利用SAS宏程序,通过设置不同参数比较其优缺点。结果Simon极小极大设计与单阶段设计相比,不会增加最大样本含量;与Gehan 二阶段设计相比,保证了在实际有效率很低时早期终止试验。结论Simon 二阶段比单阶段设计和Gehan 二阶段设计更有优势,且极小极大设计在多数情况下比最优化设计受欢迎。

     

    Abstract: Objective To compare Gehan two-stage design and Simon two-stage design in sample size calculations for phase Ⅱ clinical trials of anti-tumor drugs. Methods We explained the sample size calculation methods with a single-stage design, Gehan two-stage design, and Simon optimal two-stage and minimax two-stage designs in line with the principle of exact binomial probability. By setting up different parameters in SAS macro program, the advantages and disadvantages of these designs were compared. Results The minimax two-stage design does not increase the maximum sample size compared with the single-stage design. Compared with the Gehan two-stage design, the Simon two-stage design has the advantage of being able to determine an early termination of trials when no or low anti-tumor activities are evident. Conclusion Simon two-stage design is better than single-stage design and Gehan two-stage design. The minimax design is more popular than the optimal design.

     

© 2017 《四川大学学报(医学版)》编辑部 版权所有 cc

开放获取 本文遵循知识共享署名—非商业性使用4.0国际许可协议(CC BY-NC 4.0),允许第三方对本刊发表的论文自由共享(即在任何媒介以任何形式复制、发行原文)、演绎(即修改、转换或以原文为基础进行创作),必须给出适当的署名,提供指向本文许可协议的链接,同时标明是否对原文作了修改;不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问 https://creativecommons.org/licenses/by-nc/4.0

/

返回文章
返回